Format

Send to

Choose Destination
Acta Derm Venereol. 2009 Nov;89(6):631-5. doi: 10.2340/00015555-0731.

Vincristine, idarubicin, dexamethasone and thalidomide in scleromyxoedema.

Author information

1
Department of Dermatology, Paracelsus Medical University Salzburg, Salzburg, Austria. m.laimer@salk.at

Abstract

Scleromyxoedema is a rare disease of unknown aetiology that is characterized by progressive cutaneous mucinosis and paraproteinaemia. A variety of systemic (e.g. gastro intestinal, neurological, pulmonary, cardiac and renal) complications may lead to significant morbidity and mortality necessitating therapeutic intervention. The latter remains challenging. Numerous treatment modalities have been reported in the literature, often, however, with inconsistent responses, frequent relapses and potentially serious side-effects. Moreover, the rarity of scleromyxoedema has prevented the execution of controlled therapeutic trials. This paper discusses current proposed therapeutic strategies and reports the case of a 64-year-old male patient with progressive scleromyxoedema associated with IgG-lambda paraproteinaemia in whom monthly administrations of vincristine, idarubicin and dexamethasone in addition to daily oral thalidomide led to clinical and laboratory remission within 12 weeks.

PMID:
19997697
DOI:
10.2340/00015555-0731
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Medical Journals
Loading ...
Support Center